Drugs / VCTX211
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05565248 | Jan 2023 → Aug 2025 | type 1 diabetes mellitus | CRISPR Therapeutics AG | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VCTX211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05565248 ↗ |